XML 101 R76.htm IDEA: XBRL DOCUMENT v3.23.1
Acquisitions - EMMAC Life Sciences Limited (Details) - USD ($)
$ in Thousands
12 Months Ended
Apr. 07, 2021
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Acquisitions        
Contingent consideration payable   $ 29,109 $ 37,994 $ 1,898
Cash outflow, net of cash acquired   133,983 37,820  
EMMAC Life Sciences Limited        
Acquisitions        
Contingent consideration payable   $ 10,360 $ 35,260  
EMMAC Life Sciences Limited | Curaleaf International Holdings Limited        
Acquisitions        
Cash $ 1,490      
Accounts receivable, net 3,393      
Prepaid expenses and other current assets 535      
Inventory 7,101      
Property, plant and equipment, net 7,549      
Right-of-use assets 4,360      
Other assets 9,848      
Goodwill 64,252      
Deferred tax liabilities (49,853)      
Liabilities assumed (24,134)      
Net assets acquired 267,552      
Cash consideration, net of working capital adjustments 45,211      
Equity consideration 185,978      
Contingent consideration payable 36,363      
Total consideration 267,552      
Cash outflow, net of cash acquired 43,721      
EMMAC Life Sciences Limited | Curaleaf International Holdings Limited | Licenses        
Acquisitions        
Intangible assets 228,442      
EMMAC Life Sciences Limited | Curaleaf International Holdings Limited | Trade name        
Acquisitions        
Intangible assets 11,156      
EMMAC Life Sciences Limited | Curaleaf International Holdings Limited | Non-compete agreements        
Acquisitions        
Intangible assets 3,294      
EMMAC Life Sciences Limited | Curaleaf International Holdings Limited | Know How        
Acquisitions        
Intangible assets $ 119